Wall Street’s Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors…
Oracle Stock Is Moving Higher Wednesday: What’s Going On?
Oracle reported fourth-quarter revenue of $14.3 billion, missing the consensus estimate of $14.554 billion, according to Benzinga Pro. Oracle reported fourth-quarter adjusted earnings of $1.63 per share, missing average analyst estimates of $1.65 per share.
Top Wall Street Forecasters Revamp Korn Ferry Expectations Ahead Of Q4 Earnings
Korn Ferry (NYSE:KFY) is set to release fourth-quarter financial results, before the opening bell on Thursday. Analysts expect…
Rubrik Analysts Increase Their Forecasts After Q1 Results
Rubrik, Inc. (NYSE:RBRK) reported a year-over-year increase in first-quarter sales results and issued second-quarter revenue guidance above estimates.…
These Analysts Slash Their Forecasts On Academy Sports And Outdoors After Weak Q1 Earnings
Academy Sports And Outdoors Inc (NASDAQ:ASO) reported worse-than-expected first-quarter FY24 earnings on Tuesday. The sports goods retailer reported…
Uber To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Citigroup Analyst Sees Limited Near-Term Upside For American Express Despite Positive Long-Term Outlook – Here’s Why
Citigroup analyst initiates coverage of American Express with Neutral rating and $250 price target. Strong management, but limited near-term upside.
JP Morgan Downgrades Cleveland-Cliffs: Rising Capex And Modest Auto Demand Hamper Growth Prospects
CLF stock downgraded by JP Morgan to Neutral with lower price target. Reduced price forecasts, weak EV demand, but strong long-term prospects.
Eli Lilly’s Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi.
Google’s AI Future Bright with Potential iOS Integration and Expense Management, Says BofA Analyst
BofA Securities analyst reiterated Buy rating and $200 price target for Alphabet. Apple's new Al features may open doors for Google's AI models.